Chief Scientific Officer
Full Circles Therapeutics, Massachusetts
Dr. Wu is the co-founder and CSO of Full Circles Therapeutics, where he is dedicated to developing curative gene editing based gene/cell therapy. Before founding Full Circles Therapeutics, Dr. Wu was leading the discovery biology programs and disease prioritization at Fulcrum Therapeutics Inc. (NASDAQ:FULC), a Cambridge small molecule drug discovery biotech company. He had been with the company through the full development phases starting from the start-up, expansion, until post-IPO development.
Before Fulcrum, Dr. Wu was a senior research fellow at Whitehead institute, MIT. His research focused on neurological disorders utilizing a combination of CRISPR/Cas9 mediated genomic and epigenomic editing technology and stem cell technology. He did his PhD in Biochemistry and Structural Biology at Hongkong University of Science and Technology (HKUST) and Bachelor’s degree in Chemistry from Fudan University before he did his postdoctoral research at Johns Hopkins University School of Medicine and Howard Hughes Medical Institute. Dr. Wu has more than 30 journal publications, patents, and research and industry grants. For his work, he has received fellowship award from human frontier science program (HSFP) and NARSAD young investigator award. He was also awarded the Alfred Blalock Young Investigator Award from JHMI and President’s award from Whitehead Institute, MIT.
Disclosure information not submitted.
Circular Single-Stranded DNA-Mediated Genomic Integration
Tuesday, November 11, 2025
9:00 AM - 9:30 AM CT